CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.63%62.610.0%$958.21m
NVAXNovavax, Inc. -2.02%94.36251.8%$764.51m
AMGNAmgen, Inc. -1.04%249.041.3%$693.79m
REGNRegeneron Pharmaceuticals, Inc. -3.09%620.862.5%$663.02m
GILDGilead Sciences, Inc. 2.16%76.321.0%$630.80m
BIIBBiogen, Inc. 0.07%278.881.6%$601.57m
VRTXVertex Pharmaceuticals, Inc. -0.32%294.451.9%$475.52m
ILMNIllumina, Inc. -0.63%370.253.5%$301.18m
VXRTVaxart, Inc. -2.56%7.980.0%$286.91m
ALXNAlexion Pharmaceuticals, Inc. 0.32%108.822.0%$217.19m
BMRNBioMarin Pharmaceutical, Inc. -0.59%126.064.3%$206.81m
SRNESorrento Therapeutics, Inc. 4.00%8.061.8%$192.86m
SGENSeattle Genetics, Inc. -3.76%174.356.1%$192.39m
IMMUImmunomedics, Inc. -2.32%41.3211.0%$177.00m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%162.258.5%$166.65m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.